# First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

> **NCT01828034** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Advanced Biliary Tract Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT01828034
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828034, "First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01828034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*